Everyone should know how precise is the novel appendicitis test (APPY1) for young patients (age 2-21).
The proprietary blood test and reader helps doctors rule out appendicitis in kids without them having to undergo an expensive and cancer-risked CT scan. The breakthrough diagnostic test has already been granted marketing approval (CE Mark) in Europe where a launch in multiple countries (U.K., Germany, Italy, France, Turkey, Netherlands) is currently underway. In the U.S., APPY is currently conducting a 2,000 patient, pivotal Phase 3 study with results expected in Q4 2013.
Everyone should know how precise is the APPY1 test
NPV = Probability that a patient with a negative test result will not have the disease is 97% !!!!!
Sensitivity = Probability that a patient with the disease will have a positive test result is 97% !!!!
The market is so HUGE that we have a 685% Increase in Institutional ownership of APPY in Q1-Q2 2013 from 304,584 shares to 2,392,844 shares !!!!! at a median price of $2.40
So it's time to get your tickets for the train en route to at least $7.00
Nice review. I've read a few posts where investors wanted better numbers, but I doubt they understand what the numbers really mean. They get hung up on the 43% specificity. You don't want to miss someone with an appendicitis so thats why the specificity is low. The important thing is that the test rules out 97% & captures 97% of the individuals who may may an appendicitis.